Skip to main content
Fenggen Fu on Muck Rack

Fenggen Fu

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Fenggen

Contact Fenggen, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

B7-H3-mediated cis-inhibition of EGFR by a tumor-selective bispecific antibody enhances anti-tumor efficacy and minimizes toxicities - Nature Communications

|
By Jian Guan, Tiongsun Chia, Tianyu Zhu, Zhengguang Liao, Junjie Deng, Fenggen Fu, Weiwei Wu, Chengtao Liu, Ya Liu, Ninghuan Li, Lili Yue, Lei Cao, Jia Lu, Mengjia Zhu, Xiaomin Ling, Huilin Zheng, Shuming Lin, Shuaixiang Zhou, Kaijie He
| Nature Verified
Abstract Therapeutic targeting of epidermal growth factor receptor (EGFR) in solid tumors faces significant limitations due to on-target/off-tumor toxicities, underscoring the urgent need for tumor-selective anti-EGFR therapies. Comprehensive bioinformatics and histopathological analyses identify marked upregulation of B7-H3 across EGFR-positive malignancies, contrasting with its minimal expression in healthy tissues.
Open in Who Shared Issue with article?
See all 1 articles